Toward Expanding Understanding - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Toward Expanding Understanding
A revised book on process analytical technology could be valuable to novices and experts.


Pharmaceutical Technology
Volume 35, Issue 3

Process analytical technology (PAT) is a fairly recent innovation within the pharmaceutical industry. It has been used for a lot longer in other industries (e.g., the chemical industry). The second edition of Process Analytical Technology: Spectroscopic Tools and Implementation Strategies for the Chemical and Pharmaceutical Industries contains many revisions and some additions. Notably, the editor has added chapters on sampling, nuclear magnetic resonance, fluorescence, and acoustic chemometrics. These changes and additions reflect the developments and progress that have taken place in the five years since the publication of the first edition.


Process Analytical Technology: Spectroscopic Tools and Implementation Strategies for the Chemical and Pharmaceutical Industries, 2nd ed., Katherine A. Bakeev, Ed., Wiley, Hoboken, NJ, 2010, 576 pp, ISBN: 978-0470722077
The book contains a wealth of information, and all chapters have useful lists of references. The glossary of terms should be particularly useful to beginners in the field. As editor Katherine A. Bakeev points out in her preface, PAT continues to develop, and this book is intended as a timely update. The book is ostensibly written from a spectroscopist's viewpoint. However, that does not detract from its utility or substance because many PAT methodologies use a form of spectroscopy.

The book works on at least two levels. It is a useful overview of PAT for a beginner in the field, and it also has the detail, particularly through the cited references, to provide the experienced reader with sufficient information to meet his or her technical needs.

From this reviewer's perspective (that of a formulation scientist with experience of continuous chemical processing), three chapters stood out as the most important: those that focused on sampling, chemometrics, and applications in the pharmaceutical industry. The chapter on sampling is an excellent addition to the book. Process sampling is often the weak link in process control, and this chapter is a timely and useful reminder that sampling must be properly addressed if we are to gain the proper benefits of PAT.

The chapter about chemometrics will be heavy going for readers who do not have a good understanding of statistical theory, but it clearly illustrates the point that chemometrics requires a combination of statistical and chemical (or process) understanding. Future PAT scientists and engineers will need to be conversant with their science, technologies, and the requisite statistical methods.

The majority of the examples cited in the book concern chemical processing, and many come from outside the pharmaceutical area. This situation is inevitable, given that the chemical industry has been using PAT for longer than the pharmaceutical industry has. However, the discussion of PAT as it relates to pharmaceutical finished-product applications was perhaps more limited than it should have been. Again, this apparent shortcoming may be a consequence of the comparatively brief time that PAT has been used in such applications. However, one of the reasons for the introduction of FDA's Pharmaceutical Quality for the 21st Century initiative was to bring increased robustness to pharmaceutical finished-product manufacture.

A few minor flaws marred the book. Poor proofreading in certain sections detracted from the book's overall impression. In addition, "Chapter 8: Near-Infrared Chemical Imaging for Product and Process Understanding," was originally submitted (according to the text) with colored figures and graphs. The book is printed in black and white, however, and it is difficult to follow some of the detailed discussion because it is not clear which shade of gray corresponds to which color, particularly in some figures.

The first two chapters of the book make the connection between PAT and quality by design (QbD). QbD establishes the context of PAT in commercial manufacturing. PAT can help to establish the necessary process and attribute understanding in the development phase.

For those interested in PAT, be they novices or experienced practitioners, this second edition of Bakeev's book is a worthwhile addition to the library. For those who own the first edition, it is still a worthwhile purchase because of its revisions and widened scope.

R. Christian Moreton, PhD, is vice-president of pharmaceutical sciences at Finnbrit Consulting, Waltham, MA,
. He also is a member of Pharmaceutiacl Technology's editorial advisory board.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here